These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

438 related items for PubMed ID: 7846949

  • 1. [The pro-arrhythmic effects of anti-arrhythmia agents].
    Haverkamp W, Wichter T, Chen X, Hördt M, Willems S, Rotman B, Hindricks G, Kottkamp H, Borggrefe M, Breithardt G.
    Z Kardiol; 1994; 83 Suppl 5():75-85. PubMed ID: 7846949
    [Abstract] [Full Text] [Related]

  • 2. [The pro-arrhythmia effects of anti-arrhythmia agents--theoretical and clinical aspects].
    Steinbeck G.
    Z Kardiol; 1992; 81 Suppl 4():139-43. PubMed ID: 1290290
    [Abstract] [Full Text] [Related]

  • 3. [Ventricular pro-arrhythmic effects of anti-arrhythmia drugs].
    Jaillon P, Simon T.
    Therapie; 1992; 47(3):187-92. PubMed ID: 1295119
    [Abstract] [Full Text] [Related]

  • 4. What have clinical trials taught us about proarrhythmia?
    Skanes AC, Green MS.
    Can J Cardiol; 1996 Apr; 12 Suppl B():20B-26B. PubMed ID: 8616725
    [Abstract] [Full Text] [Related]

  • 5. Torsade de pointes with amiodarone in a patient with previous torsade during beta-receptor blockade.
    Skanes AC, Morton BC, Green MS, Tang AS.
    Can J Cardiol; 1997 Apr; 13(4):383-6. PubMed ID: 9141970
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and proarrhythmia of oral sotalol in pediatric patients.
    Pfammatter JP, Paul T, Lehmann C, Kallfelz HC.
    J Am Coll Cardiol; 1995 Oct; 26(4):1002-7. PubMed ID: 7560592
    [Abstract] [Full Text] [Related]

  • 7. Monotherapy versus combination therapy with class III antiarrhythmic agents to attenuate transmural dispersion of repolarization: a potential risk factor for torsade de pointes.
    Shah SA, Kluger J, White CM.
    Pharmacotherapy; 2007 Sep; 27(9):1297-305. PubMed ID: 17723083
    [Abstract] [Full Text] [Related]

  • 8. Safety considerations in the pharmacological management of atrial fibrillation.
    Camm AJ.
    Int J Cardiol; 2008 Jul 21; 127(3):299-306. PubMed ID: 18191470
    [Abstract] [Full Text] [Related]

  • 9. Drugs, QT interval abnormalities and ventricular arrhythmias.
    Thomas SH.
    Adverse Drug React Toxicol Rev; 1994 Jul 21; 13(2):77-102. PubMed ID: 7918900
    [No Abstract] [Full Text] [Related]

  • 10. [Torsades de pointes ventricular tachycardia induced by intravenous amiodarone].
    Makai A, Rudas L, Liszkai G, Fazekas T.
    Orv Hetil; 2003 Feb 02; 144(5):241-7. PubMed ID: 12647553
    [Abstract] [Full Text] [Related]

  • 11. Adverse cardiovascular effects of anti-arrhythmia drugs. Part I: Proarrhythmic effects.
    Libersa C, Caron J, Guedon-Moreau L, Adamantidis M, Nisse C.
    Therapie; 1992 Feb 02; 47(3):193-8. PubMed ID: 1295120
    [Abstract] [Full Text] [Related]

  • 12. Drug-induced QT-interval prolongation and proarrhythmic risk in the treatment of atrial arrhythmias.
    Shantsila E, Watson T, Lip GY.
    Europace; 2007 Sep 02; 9 Suppl 4():iv37-44. PubMed ID: 17766322
    [Abstract] [Full Text] [Related]

  • 13. Effects of antiarrhythmic drugs on QT interval dispersion--relationship to antiarrhythmic action and proarrhythmia.
    Gillis AM.
    Prog Cardiovasc Dis; 2000 Sep 02; 42(5):385-96. PubMed ID: 10768315
    [Abstract] [Full Text] [Related]

  • 14. [Drug-induced ventricular tachycardia].
    Fauchier JP, Fauchier L, Babuty D, Breuillac JC, Cosnay P, Rouesnel P.
    Arch Mal Coeur Vaiss; 1993 May 02; 86(5 Suppl):757-67. PubMed ID: 8267504
    [Abstract] [Full Text] [Related]

  • 15. Beat-to-beat variability of repolarization: a new parameter to determine arrhythmic risk of an individual or identify proarrhythmic drugs.
    Oosterhoff P, Oros A, Vos MA.
    Anadolu Kardiyol Derg; 2007 Jul 02; 7 Suppl 1():73-8. PubMed ID: 17584687
    [Abstract] [Full Text] [Related]

  • 16. [Dangerous arrhythmias].
    Gertsch M, Fuhrer J.
    Schweiz Med Wochenschr; 1993 May 01; 123(17):833-43. PubMed ID: 8497770
    [Abstract] [Full Text] [Related]

  • 17. How to evaluate class III antiarrhythmic drug efficacy clinically: the benefits and shortcomings of the invasive approach.
    Borggrefe M, Haverkamp W, Shenasa M, Hindricks G, Breithardt G.
    J Cardiovasc Pharmacol; 1992 May 01; 20 Suppl 2():S32-40. PubMed ID: 1279307
    [Abstract] [Full Text] [Related]

  • 18. [Sotalol and torsades de pointes ventricular tachycardia].
    Petersen HH, Sandøe E.
    Ugeskr Laeger; 1996 May 06; 158(19):2711-6. PubMed ID: 8744073
    [Abstract] [Full Text] [Related]

  • 19. Myocardial repolarization and drugs. Impossibility to predict the dominance of anti-arrhythmic over pro-arrhythmic effects of drugs due to differential and ventricular electrical remodeling.
    Vos MA, Crijns HJ.
    Anadolu Kardiyol Derg; 2001 Mar 06; 1(1):27-34. PubMed ID: 12122969
    [Abstract] [Full Text] [Related]

  • 20. Proarrhythmia with class III antiarrhythmic drugs: types, risks, and management.
    Hohnloser SH.
    Am J Cardiol; 1997 Oct 23; 80(8A):82G-89G. PubMed ID: 9354415
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.